NovoCure NVCR Greater China — Net revenues
Other geography segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by NovoCure in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: NovoCure’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about NovoCure's greater china — net revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is NovoCure's greater china — net revenues?
- NovoCure (NVCR) reported greater china — net revenues of $4.8M in Q1 2026.
- How has NovoCure's greater china — net revenues changed year-over-year?
- NovoCure's greater china — net revenues increased by 3.9% year-over-year, from $4.62M to $4.8M.
- What is the long-term trend for NovoCure's greater china — net revenues?
- Over 4 years (2021 to 2025), NovoCure's greater china — net revenues has grown at a -3.9% compound annual growth rate (CAGR), from $22.77M to $19.44M.
- What does greater china — net revenues mean?
- This metric represents the total gross sales generated from the sale of medical devices and associated services within the Greater China geographic region, net of returns and allowances. It serves as a key indicator of the company's market penetration, commercial adoption, and competitive performance in this specific international territory. Tracking this figure allows investors to assess the growth trajectory and regional contribution of the company's oncology treatment portfolio outside of its primary markets.